Skip to content

The David H. Koch Institute for Integrative Cancer Research At MIT

About

  • Leadership Council
  • Director's Message
  • Future
  • Scientific Advisory Board
  • FAQs
  • Administration

Faculty

Research

  • KI Approaches to Cancer
  • NCI Research Programs

facilities

  • The Koch Institute
  • Core Facilities

News and Events

  • Grants and Fellowships
  • Cancer Solutions Newsletter
  • Press Kit
  • Summer Symposium

Contact

Support

  • Make a Gift Now
  • Naming Opportunities
  • Bequests and Trusts
  • Corporate Giving
  • Gifts of Stock
  • Gifts of Other Assets

About the Koch Institute

  • Leadership Council
  • Director's Message
  • Future
  • Scientific Advisory Board
  • FAQs
  • Administration

Alison Taunton-Rigby

Alison Taunton-Rigby, PhD, OBE, has been a senior executive in the biotechnology industry for over 30 years. She is Founder, President and Chief Executive Officer of RiboNovix, Inc., an early stage biotechnology company developing novel anti-infectives that are less susceptible to drug resistance. RiboNovix has laboratories in Natick, Massachusetts.

Dr. Taunton-Rigby was President and Chief Executive Officer of Aquila Biopharmaceuticals, Inc., a public life sciences company that was merged in late 2000 with Antigenics Inc. She was also President and Chief Executive Officer of Cambridge Biotech Corporation, where she led the turn-around, re-structuring and emergence from bankruptcy. In addition, she has served as President and Chief Executive Officer of Mitotix Inc., now merged with GPC Biotech. Previous to this position, she was Senior Vice President, Biotherapeutics, at Genzyme Corporation, where she had overall responsibility for Genzyme's biotherapeutics division. Dr. Taunton-Rigby has also served in senior management positions at Vivotech Inc., Biogen, Inc. and Collaborative Research, Inc.

Dr. Taunton-Rigby received her doctorate in chemistry from the University of Bristol in England, and is a graduate of the Advanced Management Program of the Harvard Business School. She is a Director of RiverSource Funds, Healthways, Inc., Abt Associates, Inc., Idera Pharmaceuticals, Inc., the Massachusetts Women's Forum, and The Children's Hospital Boston. She is also a member of the Board of Associates of the Whitehead Institute for Biomedical Research, a Trustee of Bentley College Center for Business Ethics, an Advisor to Arboretum Ventures LLC, and also Civic Capital LLC, and a former director of the Massachusetts Biotechnology Council (MBC), and of the Biotechnology Industry Organization (BIO). In 2005 she was appointed to the Massachusetts Biomedical Research Advisory Committee (stem cell research). In 2002 Dr. Taunton-Rigby was awarded the OBE (Officer of the Order of the British Empire) by Queen Elizabeth II for her work as a leader in the research, development and promotion of biotechnology.

Alison Taunton-Rigby

Alison Taunton-Rigby

Founder & CEO
RiboNovix, Inc.